More importantly, CD8+ T cell depletion also abolished increased numbers of IFN-γ-producing tumor-specific T cells seen in mice treated with CBDCA and anti-PD-1 antibodies measured by ELISpot at Day 35 after the primary tumor implantation (Figures 5G–I). The gene discussed is CD8A; the disease is neoplasm.